Literature DB >> 1096809

Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.

J Klastersky, C Hensgens, L Debusscher.   

Abstract

Three combinations of antibiotics (cephalothin-tobramycin, cephalothin-ticarcillin, and ticarcillin-tobramycin) were administered empirically to 186 patients with cancer who were suspected of having a life-threatening infection. In approximately one-half of these patients, gram-negative infection was documented bacteriologically and consisted of septicemia in 50% of these patients. The three antimicrobial regimens were similarly effective and resulted in a favorable clinical response in approximately 55% of the patients. The administration of the cephalothin-tobramycin combination was associated with a significantly higher frequency of nephrotoxicity than that of the other two regimens.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1096809      PMCID: PMC429195          DOI: 10.1128/AAC.7.5.640

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Clinical significance of in vitro synergism between antibiotics in gram-negative infections.

Authors:  J Klastersky; R Cappel; D Daneau
Journal:  Antimicrob Agents Chemother       Date:  1972-12       Impact factor: 5.191

2.  Infections in cancer patients. Results with gentamicin sulfate therapy.

Authors:  G P Bodey; E Middleman; T Umsawadi; V Rodriguez
Journal:  Cancer       Date:  1972-06       Impact factor: 6.860

3.  Initial therapy with combination of five antibiotics in febrile patients with leukaemia and neutropenia.

Authors:  M H Tattersall; A S Spiers; J H Darrell
Journal:  Lancet       Date:  1972-01-22       Impact factor: 79.321

4.  Antimicrobial activity of tobramycin and gentamicin used in combination with cephalothin and carbenicillin.

Authors:  J Klastersky; A Henri; L Vandenborre
Journal:  Am J Med Sci       Date:  1973-07       Impact factor: 2.378

5.  Effectiveness of the carbenicillin-cephalothin combination against gram-negative bacilli.

Authors:  J Klastersky; G Swings; L Vandenborre; D Weerts; V De Maertelaer
Journal:  Am J Med Sci       Date:  1973-01       Impact factor: 2.378

6.  Causes of death in patients with cancer.

Authors:  J Klastersky; D Daneau; A Verhest
Journal:  Eur J Cancer       Date:  1972-04       Impact factor: 9.162

7.  Gentamicin treatment of staphylococcal infections.

Authors:  F Richards; C McCall; C Cox
Journal:  JAMA       Date:  1971-02-22       Impact factor: 56.272

8.  Gram-negative infections in cancer. Study of empiric therapy comparing carbenicillin-cephalothin with and without gentamicin.

Authors:  J Klastersky; A Henri; C Hensgens; D Daneau
Journal:  JAMA       Date:  1974-01-07       Impact factor: 56.272

Review 9.  Hematologic malignancies and other marrow failure states: progress in the management of complicating infections.

Authors:  A S Levine; S C Schimpff; R G Graw; R C Young
Journal:  Semin Hematol       Date:  1974-04       Impact factor: 3.851

10.  Acute renal failure associated with combined gentamicin and cephalothin therapy.

Authors:  J P Fillastre; R Laumonier; G Humbert; D Dubois; J Metayer; A Delpech; J Leroy; M Robert
Journal:  Br Med J       Date:  1973-05-19
View more
  22 in total

1.  Aminoglycosides: do we need new agents?

Authors:  H C Neu
Journal:  Drugs       Date:  1976       Impact factor: 9.546

2.  Tobramycin nephrotoxicity. A prospective clinical study.

Authors:  A Coca; J Blade; A Martinez; F Segura; E Soriano; M Ribas-Mundo
Journal:  Postgrad Med J       Date:  1979-11       Impact factor: 2.401

3.  Attenuation of experimental tobramycin nephrotoxicity by ticarcillin.

Authors:  J English; D N Gilbert; S Kohlhepp; P W Kohnen; G Mayor; D C Houghton; W M Bennett
Journal:  Antimicrob Agents Chemother       Date:  1985-06       Impact factor: 5.191

4.  Combinations of beta lactam antibiotics.

Authors:  S J Pedler; A J Bint
Journal:  Br Med J (Clin Res Ed)       Date:  1984-04-07

5.  Ceftazidime versus tobramycin-ticarcillin in the treatment of pneumonia and bacteremia.

Authors:  L A Cone; D R Woodard; D S Stoltzman; R G Byrd
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

6.  Tobramycin nephrotoxicity: failure of cefotaxime to potentiate renal toxicity.

Authors:  J Kuhlmann; G Seidel; H Grötsch
Journal:  Infection       Date:  1982       Impact factor: 3.553

7.  Ticarcillin in combination with cephalothin or gentamicin as empiric antibiotic therapy in granulocytopenic cancer patients.

Authors:  S C Schimpff; S Landesman; D M Hahn; H C Standiford; C L Fortner; V M Young; P H Wiernik
Journal:  Antimicrob Agents Chemother       Date:  1976-11       Impact factor: 5.191

8.  Activity of cefotaxime-aminoglycoside combinations against aminoglycoside-resistant Pseudomonas.

Authors:  P R Murray
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

9.  Carbenicillin plus cefazolin with or without mecillinam as an early treatment of bacteremia caused by gram-negative organisms: randomized double-blind study.

Authors:  J Klastersky; L Coppens; F Meunier-Carpentier; A P Menday
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

Review 10.  Antibacterial therapy in patients with malignancies.

Authors:  K H Mayer; S M Opal
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.